

Form PTO-1449	U.S. Department of Commerce Patent and Trademark Office	ATTY. DOCKET NO. P31828C3	SERIAL NO. Not Yet Assigned
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use several sheets if necessary)</i>		APPLICANT Stephen Alistair Smith	
		FILING DATE Herewith	GROUP Not Yet Assigned

U.S. PATENT DOCUMENTS


Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS

Document Number	Date	Country	Class	Subclass	Translation Yes No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Avandia Drug Profile. PDR Health Website - www.pdrhealth.com no date
✓	Weinstock, et al. <i>Int'l. J. Exp. Clin. Pharmacol.</i> , 54: 169-178 (1997).
✓	Iwamoto, et al., "Effect of Combination Therapy of Troglitazone and Sulphonylureas in Patients with Type 2 Diabetes Who Were Poorly Controlled By Sulphonylurea Therapy Alone". <i>Diabetic Medicine</i> , 13: 365-370 (1995).
✓	Alberti, et al., "A Desktop Guide for the Management of Non-Insulin Dependent Diabetes Mellitus (NIDDM): An Update". <i>Diabetic Medicine</i> , 11: 899-909 (1994).
✓	Iwamoto. "Usage of New Oral Anti-Diabetic Drugs". <i>Klinika</i> , 22(6) pp. 445-450 (1995).
✓	Nakano, et al., "Clinical Evaluation of a New Oral Hypoglycemic Drug, CS-045, on Daily Profile of Blood Glucose in Patients with Non-Insulin Dependent Diabetes Mellitus". <i>Rinsyou Iyaku (Clinical Medicine)</i> , 9th Vol., Supp. 3: pp. 151-164 (1993).

EXAMINER 	DATE CONSIDERED 4/1/04
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Form PTO-1449	U.S. Department of Commerce Patent and Trademark Office	ATTY. DOCKET NO. P31828C3	PRED. SERIAL NO. 10/103,326
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use several sheets if necessary)</i>		APPLICANT Stephen Alistair Smith	
		PRED. FILING DATE March 21, 2002	GROUP Not Yet Assigned

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
K	5,965,584	10/1999	Ikeda, et al.	514	342	
	US20020016287	2/7/02	Buckingham, et al.	514	3	
	US20020177612	11/28/02	Grannett, et al.	514	340	
	6,291,495	9/18/01	Rieveley	514	369	
	6,153,632	11/28/00	Rieveley	514	369	
	5,972,973	10/26/99	Whitcomb	514	342	
	5,859,037	1/12/99	Whitcomb	514	369	
	5,952,356	9/14/99	Ikeda, et al.	514	340	
	6,150,383	11/21/00	Ikeda, et al.	514	342	
	6,031,004	2/29/00	Timmins, et al.	514	635	
	4,985,862	1/23/90	Alessi, et al.	514	360	
	5,068,342	11/26/91	Zask, et al.	548	183	

FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No
K	WO 98/36755	8/1998	PCT				
	0 861 666	9/1998	EPO				
	WO 93/03724	3/1993	PCT				
	0 749 751	12/1996	EPO				
	0 306 228	3/1989	EPO				
	WO 99/03478	1/28/99	PCT				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

K	Kelley, et al., "Troglitazone", <i>Current Opinion in Endocrinology and Diabetes</i> , <u>5</u> (2): 90-96 (1998) (XP002080820).
	Scheen, et al., "Oral Antidiabetic Agents, A Guide to Selection", <i>Disease Management</i> , <u>55</u> (2): 225-236 (XP002080821).
	Scheen et al., "Drug Treatment of Non-Insulin-Dependent Diabetes Mellitus in the 1990s. Achievements and Future Developments". <i>Drugs</i> , <u>54</u> (3): 355-368 (1997) (XP002080822).
	Iwatamoto, et al., "Effect of Combination Therapy of Troglitazone and Sulphonylureas in Patients with Type 2 Diabetes Who Were Poorly Controlled by Sulphonylurea Therapy Alone". <i>Diabetic Medicine</i> , <u>13</u> (4): 365-370 (1996) (XP002064289).
	Gareth Williams. "Management of Non-Insulin-Dependent Diabetes Mellitus", <i>The Lancet</i> , <u>343</u> : 95-100 (1994).
	Kuzuya, et al., "A Pilot Clinical Trial of a New Oral Hypoglycemic Agent, CS-045, in Patients with Non-Insulin Dependent Diabetes Mellitus". <i>Diabetes Research & Clinical Practice</i> , <u>11</u> : 147-154 (1991).
	Lehmann, et al., "An Antidiabetic Thiazolidinedione is a High Affinity Ligand for Peroxisome Proliferator-Activated Receptor γ (PPAR γ)". <i>J. Biol. Chem.</i> , <u>270</u> (22): 12953-12956 (1995).

EXAMINER	DATE CONSIDERED 4/1/04
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Form PTO-1449	U.S. Department of Commerce Patent and Trademark Office	ATTY. DOCKET NO. P31828C3	PRED. SERIAL NO. 10/103,326
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use several sheets if necessary)</i>		APPLICANT Stephen Alistair Smith	
		PRED. FILING DATE March 21, 2002	GROUP Not Yet Assigned

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
✓	5,900,435	5/4/99	Martin D. Meglasson	514	565	

FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No
✓	WO 97/17975	5/22/97	PCT				
✓	WO 95/21608	8/1995	PCT				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

✓	Donnelly, et al., "Drugs and Insulin Resistance: Clinical Methods of Evaluation and new Pharmacological Approaches to Metabolism". <i>Br. J. Clin. Pharmacol.</i> , 37 : 311-320 (1994).
	Jackson, et al., "Mechanism of Metformin Action in Non-Insulin-Dependent Diabetes". <i>Diabetes</i> , 36 : 632-640 (1987).
	Hofmann, et al., "New Oral Thiazolidinedione Antidiabetic Agents Act as Insulin Sensitizers". <i>Diabetes Care</i> , 15 (8): 1075-1078 (1992).
	Foot, et al., "Improved Metabolic Control by Addition of Troglitazone to Glibenclamide Therapy in Non-Insulin Dependent Diabetics". <i>Diabetologia</i> , 38 (S1): A44 (1995).
	Whitcomb, et al., "Thiazolidinediones". <i>Exp. Opin. Invest. Drugs</i> , 4 (12): 1299-1309 (1995).
	Leif C. Groop, "Sulfonylureas in NIDDM". <i>Diabetes Care</i> , 15 (6): 737-754 (1992).
	Vialettes, et al., "Pharmacological Approach in the Treatment of Insulin Resistance". <i>Horm. Res.</i> , 38 : 51-56 (1992).
	Sohda, et al., "Studies on Antidiabetic Agents. II. Synthesis of 5-[4-(1-Methylcyclohexylmethoxy)-benzyl]thiazolidine-2,4-dione (ADD-3878) and its Derivatives". <i>Chem. Pharm. Bull.</i> , 30 (10): 3580-3600 (1982).
✓	Harold E. Lebovitz, "Stepwise and Combination Drug Therapy for the Treatment of NIDDM". <i>Diabetes Care</i> , 17 (12): 1542-1544 (1994).
✓	Iwamoto, et al., "effect of New Oral Antidiabetic Agent CS-045 on Glucose Tolerance and Insulin Secretion in Patients with NIDDM". <i>Diabetes Care</i> , 14 (11): 1083-1086 (1991).

EXAMINER

DATE CONSIDERED

4/1/04

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449	U.S. Department of Commerce Patent and Trademark Office	ATTY. DOCKET NO. P31828C3	PRED. SERIAL NO. 10/103,326
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use several sheets if necessary)</i>		APPLICANT Stephen Alistair Smith	
		PRED. FILING DATE March 21, 2002	GROUP Not Yet Assigned


U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Hotta. <i>Tonyobyoy</i> , <u>Update 10</u> , pp. 68-77, April 1994 (with translation).
	Hotta. <i>Chronic Disease</i> , <u>6(1)</u> , January 5, 1995.
	Ishida, et al., "Oral Hypoglycemic Agents – New Oral Drugs and New Strategy of Treatment". <i>Clinic All-Round</i> , 43: 2615-2621 (1994).
	Cusi, et al., "Metformin: A Review of its Metabolic Effects". <i>Diabetes Review</i> , <u>6(2)</u> : 89-131 (1998).
	Arshag D. Mooradian. "Drug Therapy of Non-Insulin-Dependent Diabetes Mellitus in the Elderly". <i>Drugs</i> , <u>51(6)</u> : 931-941 (1996).
	Windholz, et al., <i>The Merck Index</i> , <u>10th Edition</u> , pp. 635. Abstract Nos. 4300 & 4302 (1983).
	K. Doi, "New Oral Hypoglycemic Agents and Hypoglycemic Agents Under Development". <i>J. Japan Diabetes Science</i> , <u>3(Supp. 1)</u> : 962-973 (1990).
	Kramer, et al., "Differential Interaction of Glimepiride and Glibenclamide with the Beta-Cell Sulfonylurea Receptor 2 Photoaffinity-Labeling of a 65 KDA Protein by H-3 Glimepiride. <i>Biochim. et Biophys. Acta-Biomembranes</i> , <u>1191(2)</u> : 270-290 (1994).
EXAMINER	DATE CONSIDERED 4/1/04

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.